Cargando…

Amyloid-related imaging abnormalities from trials of solanezumab for Alzheimer's disease

INTRODUCTION: Solanezumab, a humanized monoclonal antibody that binds soluble amyloid beta peptide, is being developed for treatment of Alzheimer's disease (AD). METHODS: Patients (n = 2042) with mild and moderate AD were randomized 1:1 to 400-mg solanezumab or placebo infusion every 4 weeks fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carlson, Christopher, Siemers, Eric, Hake, Ann, Case, Michael, Hayduk, Roza, Suhy, Joyce, Oh, Joonmi, Barakos, Jerome
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2016
Materias:	Neuroimaging
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879647/ https://www.ncbi.nlm.nih.gov/pubmed/27239538 http://dx.doi.org/10.1016/j.dadm.2016.02.004

Ejemplares similares

Delayed-start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years
por: Liu-Seifert, Hong, et al.
Publicado: (2015)

Central pharmacodynamic activity of solanezumab in mild Alzheimer's disease dementia
por: Willis, Brian A., et al.
Publicado: (2018)

Symptomatic amyloid‐related imaging abnormalities in an APOE ε4/ε4 patient treated with aducanumab
por: VandeVrede, Lawren, et al.
Publicado: (2020)

Amyloid burden, cortical thickness, and cognitive function in the Wisconsin Registry for Alzheimer's Prevention
por: Doherty, Benjamin M., et al.
Publicado: (2015)

A systematic review and meta-analysis of (18)F-labeled amyloid imaging in Alzheimer's disease
por: Yeo, Jing Ming, et al.
Publicado: (2015)

Brain amyloid in preclinical Alzheimer's disease is associated with increased driving risk
por: Ott, Brian R., et al.
Publicado: (2016)

Clinical use of amyloid-positron emission tomography neuroimaging: Practical and bioethical considerations
por: Witte, Michael M., et al.
Publicado: (2015)

Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease
por: Salloway, Stephen, et al.
Publicado: (2021)

Multimodal neuroimaging study of cerebrovascular disease, amyloid deposition, and neurodegeneration in Alzheimer's disease progression
por: Lao, Patrick J., et al.
Publicado: (2018)

Magnetic resonance imaging measures of brain atrophy from the EXPEDITION3 trial in mild Alzheimer's disease
por: Schwarz, Adam J., et al.
Publicado: (2019)

Performance of [(18)F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer's disease
por: Salloway, Stephen, et al.
Publicado: (2017)

Asymmetrical atrophy of thalamic subnuclei in Alzheimer's disease and amyloid-positive mild cognitive impairment is associated with key clinical features
por: Low, Audrey, et al.
Publicado: (2019)

Synergistic photobiomodulation with 808-nm and 1064-nm lasers to reduce the β-amyloid neurotoxicity in the in vitro Alzheimer's disease models
por: Zhang, Renlong, et al.
Publicado: (2022)

Effect of apolipoprotein E phenotype on the association of plasma amyloid β and amyloid positron emission tomography imaging in Japan
por: Tateno, Amane, et al.
Publicado: (2017)

Amyloid‐Related Imaging Abnormalities in the DIAN‐TU‐001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease
por: Joseph‐Mathurin, Nelly, et al.
Publicado: (2022)

Machine learning of brain structural biomarkers for Alzheimer's disease (AD) diagnosis, prediction of disease progression, and amyloid beta deposition in the Japanese population
por: Shiino, Akihiko, et al.
Publicado: (2021)

Abnormal Functional Hierarchies of EEG Networks in Familial and Sporadic Prodromal Alzheimer's Disease During Visual Short-Term Memory Binding
por: Smith, Keith M., et al.
Publicado: (2022)

Assessment of amyloid β in pathologically confirmed frontotemporal dementia syndromes
por: Tan, Rachel H., et al.
Publicado: (2017)

Critical review of the Appropriate Use Criteria for amyloid imaging: Effect on diagnosis and patient care
por: Apostolova, Liana G., et al.
Publicado: (2016)

Cortical atrophy and amyloid and tau deposition in Down syndrome: A longitudinal study
por: Padilla, Concepcion, et al.
Publicado: (2022)

Amyloid β influences the relationship between cortical thickness and vascular load
por: Parker, Thomas D., et al.
Publicado: (2020)

Hippocampal subfield imaging and fractional anisotropy show parallel changes in Alzheimer's disease tau progression using simultaneous tau‐PET/MRI at 3T
por: Carlson, Mackenzie L., et al.
Publicado: (2021)

Quantile regression to characterize solanezumab effects in Alzheimer's disease trials
por: Chen, Yun-Fei, et al.
Publicado: (2016)

Longitudinal changes in amyloid positron emission tomography and volumetric magnetic resonance imaging in the nondemented Down syndrome population
por: Lao, Patrick J., et al.
Publicado: (2017)

White matter signal abnormalities in former National Football League players
por: Alosco, Michael L., et al.
Publicado: (2017)

Amyloid duration is associated with preclinical cognitive decline and tau PET
por: Koscik, Rebecca L., et al.
Publicado: (2020)

White matter microstructure disruption in early stage amyloid pathology
por: Collij, Lyduine E., et al.
Publicado: (2021)

Cerebrovascular stiffness and flow dynamics in the presence of amyloid and tau biomarkers
por: Rivera‐Rivera, Leonardo A., et al.
Publicado: (2021)

Cross-Sectional and Longitudinal Hippocampal Atrophy, Not Cortical Thinning, Occurs in Amyloid-Negative, p-Tau-Positive, Older Adults With Non-Amyloid Pathology and Mild Cognitive Impairment
por: Rane Levendovszky, Swati
Publicado: (2022)

Added value of amyloid PET in individualized risk predictions for MCI patients
por: van Maurik, Ingrid S., et al.
Publicado: (2019)

The temporal relationships between white matter hyperintensities, neurodegeneration, amyloid beta, and cognition
por: Dadar, Mahsa, et al.
Publicado: (2020)

Regional amyloid accumulation predicts memory decline in initially cognitively unimpaired individuals
por: Collij, Lyduine E., et al.
Publicado: (2021)

Qualitative and quantitative assessment of self-reported cognitive difficulties in nondemented elders: Association with medical help seeking, cognitive deficits, and β-amyloid imaging
por: La Joie, Renaud, et al.
Publicado: (2016)

Small vessel disease lesion type and brain atrophy: The role of co‐occurring amyloid
por: Heinen, Rutger, et al.
Publicado: (2020)

Accelerated MRI using intelligent protocolling and subject-specific denoising applied to Alzheimer's disease imaging
por: Ravi, Keerthi Sravan, et al.
Publicado: (2023)

Cortical and Subcortical Structural Abnormalities in Patients With Idiopathic Cervical and Generalized Dystonia
por: Wu, Yunhao, et al.
Publicado: (2022)

Microbleeds are associated with depressive symptoms in Alzheimer's disease
por: Leeuwis, Anna E., et al.
Publicado: (2017)

White matter hyperintensities are more highly associated with preclinical Alzheimer's disease than imaging and cognitive markers of neurodegeneration
por: Kandel, Benjamin M., et al.
Publicado: (2016)

Olfactory identification in subjective cognitive decline and mild cognitive impairment: Association with tau but not amyloid positron emission tomography
por: Risacher, Shannon L., et al.
Publicado: (2017)

Longitudinal trajectories of amyloid deposition, cortical thickness, and tau in Down syndrome: A deep-phenotyping case report
por: Mak, Elijah, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_h3a54j9gkd9hrir0mdhvpn3h3v